Lescarden Inc (CE) (LCAR) News

LCAR: SEC registration revoked.

https://www.sec.gov/litigation/opinions/2023/34-97070.pdf

LCAR: SEC Admin. Proceeding for severely delinquent Financials:

https://www.sec.gov/litigation/admin/2022/34-95536.pdf

Looks like the smart money is piling in.

Glenmede Trust Co becomes a shareholder owning 90k shares. Why would they purchase shares 30.9.2017 knowing the company is way behind in its reporting. Something is definitely up and cooking.

Some nice volume here today finally. Anyone hear anything?

Where is all the volume coming from? Are we done yet or just getting started?

LCAR just got hit by LBUS.

$LCAR: Starting to like the setup here

Have to agree with others here.... this looks like it wanna shimmy & Shake much higher from here.


$LCAR


$0.035

LCAR 10K and 10Q should be out soon. We have not had any trading activity lately. Any thoughts on that? Also noticed that their are out of their flagship product CATRIX OINTMENT on their website selling to general public. Worried about the product shortages, hope they can satisfy the demand. Anyone knows anything in works?

Finally a bit of volume here today. Anyone hear anything?

Hi, this seems to be news from 2006. Does anyone have some prove Lescarden inc is talking to big pharma?

Would love to get in and help promote the amazing company and opportunities

"The acquisition by Smith and Nephew was the next logical step for the company, very happy.."

For the nine months ended February 28, 2017 compared to February 28, 2016 revenues increased by 270%

LCAR going to be a biotech BEAST!!!!

LCAR already working in Spain with Smith and Nephew!

WOUND CARE now hottest biotech buyout sector, LCAR has CATRIX in demand!

LCAR to be purchased by British BIG PHARMA Smith and Nephew

Their quarterly report doesn't look so hot...

Sales increased over 270 over last year would have been higher had production companies had more product available!

New big pharma partnership announcement coming for production consistency

EU also approved wound care product

FDA approved wound care product generating good sales!

Nice small share structure only 63M O/S

Thanks, got out as fast as I got in!!

Multi site pump/promo. Good for anyone that was in prior to open or bought the nominal amounts available prior to hitting .02 within the first minute or so of trading...

Newsletter promo
https://stockpromoters.com/

otc rockstar paid promo

Whats going on with LCAR?

Something going on today? Pending?

Added a little LCAR today. I took it off my sleeper board because of the one-day promo. There's I'm sure some people here that consider themselves bagholders but the 10q will come out this week and should be excellent. Hang in there.

LCAR promo: https://www.otcdynamics.com/index.php/lcar-lescarden-inc-getting-a-promotion-starting-march-12-2013-833-am-cst/#.UT8vyBzV9zA

LCAR I hope this moves. I have 100k shares at 2.5c.

LCAR - Some Catrix products now available at Amazon

http://www.amazon.com/gp/search/ref=sr_nr_seeall_2?rh=k%3Acatrix%2Ci%3Ahpc&keywords=catrix&ie=UTF8&qid=1358791945

For the other 5 followers :)

LCAR - 10q filed last week shows revenues up 1,300% to over $1/4 million for three months. 10q also shows this was not a one shot deal; they have over $250,000 in accounts receivable and over $210,000 in inventory (which should become over $600,000 in revenues). I'm anticipating sales to grow from these levels, and the last time they had $1,000,000 in annual revenues the share price was .40. I'm very comfortable holding this.

LCAR - From 10q filed 1/11/13:

"The Company’s revenues increased in the fiscal quarter ended November 30, 2012 compared to November 30, 2011 by 1,300% or $250,377 due to the resumption of production operations at the Company’s sole raw material supplier and the fulfillment of outstanding purchase orders to European distributors"

LCAR seller gone for now. Almost exactly 150,000 shares traded with NITE on the ask every day at around .04 since 11/23. NITE at .40 now

LCAR mentioned in this report. Don't think I'll pay $4,950 to read it though :)

http://www.researchandmarkets.com/research/85zhqj/chitin_and

LCAR someone is accumulating .04s lately

Dear diary~

Nice $1,500 buy yesterday at .03. Wasn't me, already in, holding with patience

.03x.068

Some older info concerning one of LCAR's products. Just dreaming here, maybe there's some developments requiring the need for all that new inventory they're getting :)

http://www.catrix.com

"A phase II study of Catrix-S in solid tumors.

Romano CF, Lipton A, Harvey HA, Simmonds MA, Romano PJ, Imboden SL.
Catrix-S is an acidic mucopolysaccharide complex derived from bovine tracheal cartilage. This material was administered by weekly subcutaneous injection (5.0-7.5 g/week) to nine patients with progressive metastatic malignancy. One complete response was seen in a patient with metastatic renal cell carcinoma to the lungs. Eight patients had progression of their disease. No undue toxicity and no consistent immunologic alteration was noted."
http://www.ncbi.nlm.nih.gov/pubmed/3878861

"Catrix: an easy-to-use collagen treatment for wound healing.
Collagen plays a major role in wound healing. Its presence is important in all stages of the healing process. Catrix is a new collagen wound-healing powder that has been shown to be effective in the treatment of wounds healing by secondary intent such as pressure ulcers, venous stasis ulcers and diabetic ulcers as well as second-degree burns and post-radiation dermatitis. Catrix has also been shown to be effective in the treatment of wounds unresponsive to conventional treatments. It promotes the growth of fibroblasts and keratinocytes in the wound, prevents loss of fluid from the wound and protects the wound from bacterial infections and other agents. Catrix is biodegradable and therefore does not require removal from the wound bed before re-application."
http://www.ncbi.nlm.nih.gov/pubmed/16245393

Based on their recent history LCAR is, imo, fairly valued now at .03. Now that their supply problems have been corrected I expect, within a few months, a return to their condition of a few years ago when they were worth .15. Their products:
http://www.catrix.com/home/index.htm

My interest in LCAR does not stem from now or the past but the future. Specifically, the chairman of the board paying $200,000 (via the purchase of common shares) specifically for the company's purchase of inventory. This is very, very friendly financing, as opposed to a promissory note, convertible debenture, or other possibly toxic financing from outsiders (Mr. Maxwell now owns over 60% of the outstanding stock). Why would a company need to more than triple their inventory level unless they were anticipating a robust growth in sales?

Reading their 10k filings from the last few years shows the promise that their products may provide, based on their own and other independent studies and trials. They have had limited success with market penetration but have a good base of repeat customers, mostly physicians in Asia.

Revenue growth could be coming from many sources. But there's a chance that new things could happen, specifically (from a 2010 study):

"The following have been reported from preclinical studies of the effect of powdered cartilage on cancer cells in vitro (outside of the body):
•In a published laboratory study, a powdered form of bovine cartilage called Catrix slowed the growth of human cancer cells by half or more. It is not clear if Catrix had this effect only on cancer cells, because its effect the growth of normal cells was not tested. It is also not known if the dose used in the laboratory study could safely be used in people."
http://www.cancer.gov/cancertopics/pdq/cam/cartilage/patient/page2

Success with their products in the field of cancer treatment would certainly be a game-changer for them. I consider that a pipe dream until I see further proof, but based on the company being, imo, "real," I'm willing to sit and wait on it. Meanwhile I do expect significant growth in sales of their regular products to be reported in the next 10q (Jan 2013).

Other reasons I like LCAR

Never been promoted
No toxic financing
No bagholders

what kind of value/pps does LCAR have iyo

LCAR 10Q out this week. Not much new in it but here's some tidbits from SEC filings in the last few months that lead me to believe there will be solid improvement in their revenues in the near future, specifically the purchasing of $200,000 worth of inventory, a huge increase from recent inventory levels.

"Raw material production delays and regulatory recertification of packaging facilities have resulted in order fulfillment lead times of greater than six months. Ongoing supply and production disruptions prevented fulfillment of $100,000 of customer purchase orders for the quarter ended August 31, 2012. The results of operations for the interim periods are not necessarily indicative of results to be expected for a full year's operations..."

"completion of the regulatory recertification of the Company’s packaging facility"

"We plan to add human resources and decrease reliance on outside sources of expertise as the Company returns to profitability."

"Pursuant to the Stock Purchase Agreement, the Company will issue a number of shares of common stock to the majority shareholder and Chairman of the Board equal $200,000 divided by average closing market price of the Company’s common stock during the three weeks preceding the date of the closing, or $0.023133 per share. Upon issuance, Maxwell will receive 8,645,533 shares of common stock resulting in a beneficial ownership of 30,512,378 shares, or 62.63%.
The proceeds from the issuance of stock are to be used for the purchase of inventory."

"The Company has no material commitments for capital expenditures at August 31, 2012."

From the LCAR 8k filed 9/26/12:
"Pursuant to the Stock Purchase Agreement, the Company will issue a number of shares of common stock to the majority shareholder and Chairman of the Board equal $200,000 divided by average closing market price of the Company’s common stock during the three weeks preceding the date of the closing, or $0.023133 per share. Upon issuance, Maxwell will receive 8,645,533 shares of common stock resulting in a beneficial ownership of 30,512,378 shares, or 62.63%. The proceeds from the issuance of stock are to be used for the purchase of inventory."

I find this interesting for 2 reasons:
1. No "toxic financing," insiders are financing inventory on a favorable basis and, imo, wouldn't do so unless a large increase in inventory was needed to support future sales growth.
2. $200,000 added to the current inventory level raises it to above where it was in 2008, when revenue was much higher than today's, and LCAR was trading at .15.

So, in my humble opinion, things are looking up for LCAR. But definitely a patience play, a rare buy and hold.

Next 10q should come out soon

Good to see LCAR doesn't need to pursue "toxic" financing. Insiders still have faith in the company's prospects. From 8k filed 9/26/12:

"Pursuant to the Stock Purchase Agreement, the Company will issue a number of shares of common stock to the majority shareholder and Chairman of the Board equal $200,000 divided by average closing market price of the Company’s common stock during the three weeks preceding the date of the closing, or $0.023133 per share. Upon issuance, Maxwell will receive 8,645,533 shares of common stock resulting in a beneficial ownership of 30,512,378 shares, or 62.63%.

The following sets forth the information required by Item 701 of Regulation S-K with respect to the unregistered sale of equity securities the Company completed on September 24, 2012:

? Effective August 10, 2012, the Company entered into a Stock Purchase Agreement with Maxwell pursuant to which Maxwell agreed to purchase, and the Company agreed to sell and issue 8,645,533 shares of common stock, $.001 par value for an aggregate purchase price of $200,000. The shares issued pursuant to the Stock Purchase Agreement were issued exclusively to one person who qualified as an "accredited investor" within the meaning of Rule 501(a) of Regulation D under the Securities Act of 1933 as amended (the "Securities Act"). The shares issued are “restricted securities” under the Securities Act.

? The Company paid no fees or commissions in connection with the issuance of the Shares.The sale of the Securities was undertaken without registration under the Securities Act in reliance upon an exemption from the registration requirements of the Securities Act set forth in Section 4(2) there under. The investor qualified as an "accredited investor" within the meaning of Rule 501(a) of Regulation D. The Company did not engage in any public advertising or general solicitation in connection with this transaction, and the investor was provided with disclosure of all aspects of the Company’s business, including reports filed with the Securities and Exchange Commission and other financial, business and corporate information.

? The proceeds from the issuance of stock are to be used for the purchase of inventory."

Something's up. LCAR off pinks.
Share if you can.